Psychopharmacology

, Volume 171, Issue 3, pp 250–258

Influence of mirtazapine on the sexual behavior of male rats

  • Augusta Benelli
  • Claudio Frigeri
  • Alfio Bertolini
  • Susanna Genedani
Original Investigation

Abstract

Rationale

Impairment of sexual activity is one of the most frequent side effects of antidepressant drugs. The increase in the synaptic concentrations of serotonin seems to be mainly responsible. Mirtazapine is a novel antidepressant that increases the synaptic concentrations of both noradrenaline and serotonin; moreover, it is an antagonist at 5-HT2C receptors, whose activation is considered to be responsible for some typical effects of serotonin on the ejaculation process (retardation of ejaculation, anorgasmia).

Objectives

To study the influence of mirtazapine on copulatory performance and sexual motivation in male rats, in comparison—or in combination—with fluoxetine.

Methods

Copulatory performance was studied either in sexually experienced or in sexually naive rats; sexual motivation was studied in sexually experienced rats. Mirtazapine (1, 5 or 10 mg/kg), fluoxetine (10 mg/kg), and the combination of mirtazapine + fluoxetine (10+10 mg/kg) were subcutaneously (s.c.) administered either acutely or daily for 13 days.

Results

After acute administration, mirtazapine decreased mount latency (ML) and intromission latency (IL), and increased mount frequency (MF) and ejaculation latency (EL). Fluoxetine had no significant effect on any of the sexual behavior parameters. After a 13-day treatment, mirtazapine increased ML, IL and MF; fluoxetine increased ML, IL and the intercopulatory interval (ICI); the addition of mirtazapine to fluoxetine produced a reduction of ICI and an increase of MF. Moreover, mirtazapine significantly improved the performance of rats in the sexual motivation test.

Conclusions

The present results show that, on the whole, the acute administration of mirtazapine improves several parameters of the copulatory performance of male rats and strongly stimulates sexual motivation, while the repeated administration produces minor, conflicting effects. This effect of mirtazapine on male rat sexual behavior is to be ascribed to the antagonism at brain α2 adrenergic auto- and hetero-receptors, with consequent increased release of noradrenaline and serotonin, and antagonism at 5-HT2C receptors, which are involved in the negative influence of serotonin on male sexual behavior.

Keywords

Mirtazapine Fluoxetine Antidepressants Sexual behavior Male rat 

References

  1. Aizenberg D, Zhemishlany Z, Weizman A (1995) Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 18:320–324PubMedGoogle Scholar
  2. American Psychiatric Association (1995) Diagnostic and statistical manual of mental disorders, 4th edn. rev. American Psychiatric Press, WashingtonGoogle Scholar
  3. Baldwin DS (1995) Psychotropic drugs and sexual dysfunction. Int Rev Psychiatry 7:261–273Google Scholar
  4. Balon R, Yeragani VK, Pohl R, Ramesh C (1993) Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 54:209–212Google Scholar
  5. Beach FA (1956) Characteristics of masculine “sex drive”. In: Jones MR (ed) Nebraska symposium on motivation. University of Nebraska Press, Lincoln, pp 1–31Google Scholar
  6. Benelli A, Zanoli P, Bertolini A (1990) Effect of clenbuterol on sexual behavior in male rats. Physiol Behav 47:373–376PubMedGoogle Scholar
  7. Benelli A, Arletti R, Basaglia R, Bertolini A (1993) Male sexual behaviour: further studies on the role of alpha-2 adrenoceptors. Pharmacol Res 28:35–43PubMedGoogle Scholar
  8. Bitran D, Hull EM (1987) Pharmacological analysis of male rat sexual behavior. Neurosci Biobehav Rev 11:365–389PubMedGoogle Scholar
  9. Boyarsky BK, Haque W, Rouleau MR, Hirschfeld RM (1999) Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 9:175–179PubMedGoogle Scholar
  10. Cantor JM, Binik YM, Pfaus JG (1999) Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin. Psychopharmacology 144:355–362PubMedGoogle Scholar
  11. Clark JT, Kalra PS, Kalra SP (1987) Effects of a selective alpha-1 adrenoceptor agonist, methoxamine, on sexual behavior and penile reflexes. Physiol Behav 40:747–753Google Scholar
  12. Clark JT, Smith ER, Davidson JM (1984) Enhancement of sexual motivation in male rats by yohimbine. Science 225:847–849PubMedGoogle Scholar
  13. Clark JT, Smith ER, Davidson JM (1985) Testosterone is not required for the enhancement of sexual motivation by yohimbine. Physiol Behav 35:517–521PubMedGoogle Scholar
  14. Crenshaw TL, Goldberg JP (1996) Sexual pharmacology: drugs that affect sexual function. WW Norton, New YorkGoogle Scholar
  15. De Boer TH, Maura G, Raiteri M, De Vos CJ, Wieringa J, Pinder RM (1988) Neurochemical and automic pharmacological profile of the 6-aza-analogue of mianserine, Org 3770 and its enantiomers. Neuropharmacology 27:399–408PubMedGoogle Scholar
  16. De Boer TH, Nefkens F, Van-Helvoirt A (1994) The alpha-2 adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 253:5–6CrossRefGoogle Scholar
  17. De Boer TH, Nefkens F, Van Helvoirt A, Van Delft AM (1996) Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 277:852–860PubMedGoogle Scholar
  18. Dewsbury DA (1972) Effect of tetrabenazine on the copulatory behavior in male rats. Eur J Pharmacol 17:221–226PubMedGoogle Scholar
  19. Dorevitch A, Davis H (1994) Fluvoxamine-associated sexual dysfunction. Ann Pharmacother 28:872–874PubMedGoogle Scholar
  20. Farah A (1999) The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitors treatment due to sexual dysfunction. Int Clin Psychopharmacol 14:253–255PubMedGoogle Scholar
  21. Gelenberg AJ, Laukes C, McGahuey C, Okayli G, Moreno F, Zentner L, Delgado P (2000) Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 61:356–360PubMedGoogle Scholar
  22. Gessa GL, Tagliamonte A (1974) Role of brain monoamines in male sexual behaviour. Life Sci 14:425–436PubMedGoogle Scholar
  23. Gitlin MJ (1995) Effects of depression and antidepressants on sexual functioning. Bull Manninger Clin 59:232–248Google Scholar
  24. Harrison W, Rabkin J, Stewart JW, McGrath PJ, Tricamo E, Quitkin F (1986) Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 47:346–349PubMedGoogle Scholar
  25. Herman J, Brotman A, Pollack M, Falk W, Biederman J, Rosenbaum J (1990) Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 51:25–27Google Scholar
  26. Hillegaart V, Ahlenius S, Larsson K (1989) Effects of local application of 5-HT into the median and dorsal raphe nuclei on male rat sexual and motor behavior. Behav Brain Res 33:279–286PubMedGoogle Scholar
  27. Hirschfeld RM (1999) Care of the sexually active depressed patient. J Clin Psychiatry 60:32–35Google Scholar
  28. Hsu JH, Shen WW (1995) Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 25:191–201PubMedGoogle Scholar
  29. Jacobsen FM (1992) Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 53:119–122Google Scholar
  30. Kent JM (2000) SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355:911–918PubMedGoogle Scholar
  31. Lane R, Baldwin D, Preskorn S (1995) The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 9:163–178Google Scholar
  32. Ludovico GM, Corvasce A, Pagliarulo G, Cirillo-Marucco E, Marano A, Pagliarulo A (1996) Paroxetine in the treatment of premature ejaculation. Br J Urol 77:881–882PubMedGoogle Scholar
  33. Mendels J, Camera A, Sikes C (1995) Sertraline treatment for premature ejaculation. J Clin Psycopharmacol 15:341–346Google Scholar
  34. Meston CM, Gorzalka BB (1992) Psychoactive drugs and human sexual behaviour: the role of serotonergic activity. J Psychoactive Drugs 24:1–40PubMedGoogle Scholar
  35. Modell JG, Katholi CR, Modell JD, De Palma RL (1997) Comparative sexual side effect of bupropion, fluoxetine, paroxetine and sertraline. Clin Pharmacol Ther 61:476–487PubMedGoogle Scholar
  36. Mos J, Mollet I, Tolboom JTBM, Waldinger MD, Olivier B (1999) A comparison of the effects of different serotonin reuptake blockers on sexual behaviour of the male rat. Eur Neuropsychopharmacol 9:123–135PubMedGoogle Scholar
  37. Murdoch D, MacTavish D (1992) Sertraline: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 44:604–624PubMedGoogle Scholar
  38. Patterson W (1993) Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 54:71Google Scholar
  39. Segraves RT (1995) Antidepressant-induced orgasm disorder. J Sex Marital Ther 21:192–201PubMedGoogle Scholar
  40. Smith ER, Davidson JM (1990) Yohimbine attenuates aging-induced sexual deficiencies in male rats. Physiol Behav 47:631–634PubMedGoogle Scholar
  41. Smith ER, Lee RL, Schnur SL, Davidson JM (1987) Alpha-2 adrenoceptor antagonists and male sexual behaviour. I. Mating behavior. Physiol Behav 41:7–14PubMedGoogle Scholar
  42. Solyom L, Solyom C, Ledwidge B (1990) The fluoxetine treatment of low-weight, chronic bulimia nervosa. J Clin Psychopharmacol 10:421–425PubMedGoogle Scholar
  43. Tagliamonte A, Tagliamonte P, Gessa GL, Brodie BB (1969) Compulsive sexual activity induced by p-chlorophenylalanine in normal and pinealectomized male rats. Science 166:1433–1435PubMedGoogle Scholar
  44. Taylor G, Bardgett M, Csernansky J, Early T, Haller J, Scherrer J, Womack S (1996) Male reproductive systems under chronic fluoxetine or trimipramine treatment. Physiol Behav 59:479–484PubMedGoogle Scholar
  45. Waldinger MD, Hengeveld MW, Zwinderman AH (1994) Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 151:1377–1379PubMedGoogle Scholar
  46. Waldinger MD, Hengeveld MW, Zwinderman AH (1997) Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double blind, randomized, dose response study. Br J Urol 79:592–595PubMedGoogle Scholar
  47. Waldinger MD, Berendsen HHG, Block BFM, Oliver B, Holstege G (1998) Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of serotonergic system. Behav Brain Res 92:111–118PubMedGoogle Scholar
  48. Wieseler Frank JL, Hendricks SE, Olson CH (2000) Multiple ejaculations and chronic fluoxetine: effects on male rat copulatory behavior. Pharmacol Biochem Behav 66:337–342PubMedGoogle Scholar
  49. Yells DP, Prendergast MA, Hendricks SE, Nakamura M (1994) Fluoxetine-induced inhibition of male rat copulatory behaviour: modification by lesions of the nucleus paragigantocellularis. Pharmacol Biochem Behav 49:121–127PubMedGoogle Scholar
  50. Yells DP, Prendergast MA, Hendricks SE, Miller ME (1995) Monoaminergic influences on temporal patterning of sexual behavior in male rats. Physiol Behav 58:847–852PubMedGoogle Scholar
  51. Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C (1991) The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 52:66–68PubMedGoogle Scholar
  52. Zohar J, Kaplan Z, Benjamin J (1994) Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. J Clin Psychiatry 55:86–88Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Augusta Benelli
    • 1
  • Claudio Frigeri
    • 1
  • Alfio Bertolini
    • 2
  • Susanna Genedani
    • 1
  1. 1.Department of Biomedical Sciences, Section of PharmacologyUniversity of Modena and Reggio EmiliaModenaItaly
  2. 2.Department of Internal Medicine, Section of Toxicology and Clinical PharmacologyUniversity of Modena and Reggio EmiliaModenaItaly

Personalised recommendations